Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment. (Core HTA 2)

Country	Agency	Status	Link	Details on adaptation process	Contact information
Croatia	AAZ	2015	Link to the summary	Summary of information from the report for decision makers and website	Mirjana Huic (Mirjana.Huic@aaz.hr)
Spain	ISCII	2016		Summary of information from the report	Iñaki Imaz

OUR NETWORK

CAREERS

HELP

eunethta@zinl.nl

CONTACT US

This website was produced under the Third EU Health Programme through a service contract with the European Health and Digital Executive Agency (HaDEA) acting under the mandate from the European Commission. The information and views set out in this website are those of the author(s) and do not necessarily reflect the official opinion of the Commission/Executive Agency. The Commission/Executive Agency do not guarantee the accuracy of the data included in this website. Neither the Commission/Executive Agency nor any person acting on the Commission’s/Executive Agency’s behalf may be held responsible for the use which may be made of the information contained therein.